← Back to Clinical Trials
Recruiting NCT07205341

NCT07205341 Detecting Changes in Arterial Blood Volume and Cardiac Efficiency

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07205341
Status Recruiting
Phase
Sponsor HemoCept Inc.
Condition Aortic Valve Stenosis
Study Type OBSERVATIONAL
Enrollment 20 participants
Start Date 2025-04-29
Primary Completion 2026-09

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 20 participants in total. It began in 2025-04-29 with a primary completion date of 2026-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of this Pilot Study is to demonstrate the efficacy of the Hemocept device in detecting changes in arterial blood volume and cardiac efficiency.

Eligibility Criteria

Inclusion Criteria: * Subjects or representatives must have voluntarily signed the informed consent form before any study related procedures. * Subjects can be any gender but must be between (and including) the ages of 18 and 80. * Subject ls being treated by the participating healthcare facility . ., Subject requires a trans-aortic valve replacement. * Subject is able and willing to provide informed consent and HIPM authorization. * Subject is able and willing to meet all study requirements. Exclusion Criteria: * Subject is pregnant, breast-feeding, or intends to become pregnant during the course of the study. * Subject has a personal medical history that includes: * Long O-T syndrome * Cardiac channelopathies * Seizures

Contact & Investigator

Central Contact

Katharine Adkins

✉ kathari.adkins@bch.org

📞 303-442-2395

Principal Investigator

Jamie Doucet, MD

PRINCIPAL INVESTIGATOR

Boulder Heart

Frequently Asked Questions

Who can join the NCT07205341 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Aortic Valve Stenosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07205341 currently recruiting?

Yes, NCT07205341 is actively recruiting participants. Contact the research team at kathari.adkins@bch.org for enrollment information.

Where is the NCT07205341 trial being conducted?

This trial is being conducted at Boulder, United States.

Who is sponsoring the NCT07205341 clinical trial?

NCT07205341 is sponsored by HemoCept Inc.. The principal investigator is Jamie Doucet, MD at Boulder Heart. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology